Ted Okon, BS, MBA


Executive Director
Community Oncology Alliance
Washington, DC

Authored Items

How Will We Pay for Cancer Treatment?

November 2012, Vol 3, No 8 - VBCC Perspectives

?With the fanfare of a New York Times Op-Ed piece by Peter B. Bach, MD, and colleagues, the announcement was made that Memorial Sloan-Kettering Cancer Center (MSKCC) would ex­clude the new colorectal cancer drug ziv-aflibercept (Zaltrap) from its formulary. Regardless of questions raised about the accuracy of the cost and the dosing comparisons and certain conflicts, the question is—Will the MSKCC decision influence community oncology clinics to consider a similar restriction?

[ Read More ]